Abiopharma

News list

Director Lillie Charisse R 🟢 acquired 883 shares (1 derivative) of EXELON CORP (EXC) at $49.82 Transaction Date: Mar 31, 2026 | Filing ID: 000004

Full text

News bot April 1, 2026, 7:28 p.m.
🔍 Lillie Charisse R (Director)

Company: EXELON CORP (EXC)

Report Date: 2026-03-31
Transaction Summary:
- Total transactions: 3
- Derivative instruments: 1
- Holdings reported: 1
- Total shares acquired: 883
- Total shares held: 7,246
Detailed Transactions and Holdings:
- Acquired 878 shares of Common stock- deferred stock units at $49.82 per share (Direct)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 12,554.00 | transaction_form_type: 4 | Footnotes: F1
- Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: H | shares_owned_after: 7,246.00
- Acquired 5 shares of Deferred phantom share equivalents (Derivative)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,855.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2, F3
Footnotes:
- F1: Balance includes 98 additional shares acquired through automatic dividend reinvestment.
- F2: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors.
- F3: Balance includes 32 additional phantom share equivalents accrued to the account through automatic dividend reinvestment.